Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 0.59 |
| ▸ | HTR1A | P08908 | 1/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.37 |
| ▸ | HSPA5 | P11021 | 2/20 | 0.35 |
| ▸ | CA1 | P00915 | 1/20 | 0.35 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.34 |
| ▸ | CDC25B | P30305 | 2/20 | 0.34 |
| ▸ | NT5E | P21589 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18787315 | 0.91 | PDE2A (0.52) | PDE2AHTR1ABCHEHSPA5CA1 | |
| SCHEMBL18787314 | 0.90 | PDE2A (0.51) | PDE2AHTR1ABCHEHSPA5CA1 | |
| SCHEMBL18788249 | 0.87 | PDE2A (0.49) | PDE2AHTR1ABCHEHSPA5CA1 | |
| SCHEMBL18787318 | 0.86 | PDE2A (0.48) | PDE2AHTR1ABCHEHSPA5CA1 | |
| SCHEMBL18787319 | 0.85 | PDE2A (0.50) | PDE2AHTR1ABCHEHSPA5CA1 | |
| SCHEMBL29398438 | 0.83 | PDE2A (0.46) | PDE2AHTR1ABCHENT5E | |
| SCHEMBL29397151 | 0.83 | PDE2A (0.45) | PDE2AHTR1ABCHECA1CA2 | |
| SCHEMBL22579737 | 0.83 | PDE2A (0.45) | PDE2AHTR1ABCHECA1CA2 | |
| SCHEMBL20653964 | 0.82 | PDE2A (0.47) | PDE2AHTR1ABCHEHSPA5CA1 | |
| SCHEMBL20404030 | 0.81 | PDE2A (0.42) | PDE2AHTR1AHSPA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | BIOARDIS LLC | 2022-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220204539-A1 | CD73 INHIBITORS | ENTPD5, ENTPD1, ENTPD2 | PDE2A 431/4885HTR1A 2118/4885BCHE 663/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.